PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.23%
EBIT growth above 1.5x AGEN's 3.18%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
45.56%
Operating income growth above 1.5x AGEN's 3.18%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
30.89%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
30.77%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
30.77%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.49%
OCF growth above 1.5x AGEN's 43.38%. David Dodd would confirm a clear edge in underlying cash generation.
98.49%
FCF growth above 1.5x AGEN's 43.24%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
94.54%
10Y OCF/share CAGR above 1.5x AGEN's 46.84%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
94.54%
5Y OCF/share CAGR 1.25-1.5x AGEN's 75.06%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
94.54%
3Y OCF/share CAGR 1.25-1.5x AGEN's 69.67%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
-8.80%
Negative 10Y net income/share CAGR while AGEN is at 15.48%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-8.80%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-8.80%
Negative 3Y CAGR while AGEN is 46.19%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-273.39%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-273.39%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-273.39%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.09%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-4.63%
We have a declining book value while AGEN shows 14.85%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
0.22%
We have some new debt while AGEN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-43.90%
We cut SG&A while AGEN invests at 6.81%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.